Alkermes plc (ALKS)

Market Cap	6.16B +23.1%
Revenue (ttm)	1.56B +3.2%
Net Income	152.72M -56.7%
EPS	0.91 -56.5%
Shares Out	166.68M
PE Ratio	40.66
Forward PE	21.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,817,767
Open	37.21
Previous Close	37.00
Day's Range	36.88 - 37.94
52-Week Range	25.17 - 39.56
Beta	0.26
Analysts	Buy
Price Target	45.44 (+22.88%)
Earnings Date	May 5, 2026

About ALKS

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramu...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jul 16, 1991
• Employees: 2,050
• Stock Exchange: NASDAQ
• Ticker Symbol: ALKS
• Website: https://www.alkermes.com

Financial Performance

In 2025, Alkermes's revenue was $1.48 billion, a decrease of -5.25% compared to the previous year's $1.56 billion. Earnings were $241.66 million, a decrease of -34.16%.

Analyst Summary

According to 17 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price target is $45.44, which is an increase of 22.88% from the latest price.

Price Target

$45.44

(22.88% upside)

Analyst Consensus: Buy